Abstract: This patent describes formaldehyde free or formaldehyde reduced binders useful, for example, in a fiber based composite material such as glass or other mineral fiber insulation, non-woven fabric or wood-based board. In one example, melamine is used as an acidic solution or a salt. The salt or solution is used to create an aqueous binder with other components such as a polyol and a crosslinker. A preferred polyol is a nanoparticle comprising high molecular weight starch. In other examples, binders include mixtures of a polyol with urea and a crosslinker. In other examples, a multi-component nanoparticle is made by reacting a polyol such as starch in an extruder with an insolubilizer such as melamine or urea. The resulting particles are mixed with water, optionally with other components such as an additional crosslinker, to create an aqueous binder.

Abstract: A circuit for use with PWM signal having first pulse and a second pulse, wherein the first pulse has a period and a first duty cycle, and the second pulse has the period and a second duty cycle. The period has clock information therein, the first duty cycle has first data information therein, and the second duty cycle has second data information therein. The circuit includes a first integrating component and a second integrating component. The first integrating component can generate a first voltage corresponding to the first duty cycle and a second voltage corresponding to the first duty cycle. The second integrating component can generate a third voltage corresponding to the second duty cycle and a fourth voltage corresponding to the second duty cycle.

Abstract: A curable aqueous binder has two primary components. The first component is a bio-based material or mixture of bio-based materials such as starch or polyvinyl alcohol. The second component is one or more compounds selected from the group of urea, polyurea and substituted urea. The first and second components make up most (i.e. 50% or more) of all solids in the binder. The dry weight of the second component is preferably 25% or more of the dry weight of the first component. The solids content of the binder is preferably between 6 wt % and 20 wt %. A method of making a mineral fiber product includes a step of curing a binder as described above in situ on a mass of mineral fibers at a temperature of 175 degrees C. or more. A preferred binder is a mixture of urea and starch in a ratio by weight between 50-50 and 80-20 in water at a solids content of 10-20 wt %, substantially without other components, and may be used as a replacement for formaldehyde or petrochemical based resins.

Abstract: A curable aqueous binder has two primary components. The first component is a bio-based material or mixture of bio-based materials such as starch or polyvinyl alcohol. The second component is one or more compounds selected from the group of urea, polyurea and substituted urea. The first and second components make up most (i.e. 50% or more) of all solids in the binder. The dry weight of the second component is preferably 25% or more of the dry weight of the first component. The solids content of the binder is preferably between 6 wt % and 20 wt %. A method of making a mineral fiber product includes a step of curing a binder as described above in situ on a mass of mineral fibers at a temperature of 175 degrees C. or more. A preferred binder is a mixture of urea and starch in a ratio by weight between 50-50 and 80-20 in water at a solids content of 10-20 wt %, substantially without other components, and may be used as a replacement for formaldehyde or petrochemical based resins.

Abstract: An improved for preparing Olanzapine Form I of Formula 1 in the presence of one solvent or a mixture of solvents.

Abstract: The present invention relates to an improved process for the preparation of [R-(E)]-1-[[[1-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropaneacetic acid, monosodium salt of Formula (I).

Abstract: An improved for preparing Olanzapine Form I of Formula 1 in the presence of one solvent or a mixture of solvents.

Abstract: There is described a process for the preparation of a pure amorphous form of cefuroxime axetil which involves dissolving crystalline cefuroxime axetil in acetic acid including at least 5% v/v water and recovering said amorphous form of cefuroxime axetil from the solution by the addition of additional water, the solution being added all at once to the additional water being present in a volume which is sufficient to precipitate said amorphous cefuroxime axetil.